- Email: [email protected]
5558865 HIV immunotherapeutics
PATENT ABSTRACTS
interference by the cellularcomponents of whole blood. The method includes contacting the whole blood with a test device including a filter pad comprising a suitable carrier matrix homogeneously incorporating therein a separating reagent composition comprising a) separating reagent, like an agglutinin, such as a blood type nonspecific lectin; a coagulant, such as a thrombin or a thrombin-like compound; or a mixture thereof, and b) a nonhamolyticsurfactant, like an ethoxylated or propoxylated nonionic or anionic surfactant, such that the cellular components of the whole blood are separated from the plasma or serum as the blood permeates through the filter pad, The essentially cell-free plasma or serum then saturates a test pad that is in contact with the ftlter pad. After the plasma or serum saturates the test pad, the test pad is examined for a qualitative or quantitative response to a predetermined soluble constituent of the whole blood.
5558865 HIV I M M U N O T H E R A P E U T I C S Ohno Tsuueya Boston, MA, UNH'ED STATES Assigned to Nissin Shokuhin Kabushiki Kaisha The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gpl20 protein or its precursor gpl60 protein comprising the amino acid sequence set out in SEQ ID NO: 1,G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-I strains MN and f I B as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC liB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV- 1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC FIB 10726 are specifically disclosed. Pharmaceutical compositions of the invention are projected to be useful in the passive iltllnuDiT~tion treatment of animals, especially humans, susceptible to or infected with HIV-I.
445
5558869 M A J O R PEANUT A L L E R G E N ARAHH Burks A Wesley; Helm Ricki M Little Rock, AR, UNITED STATES Assigned to University of Arkansas Peanut allergen Ara h H was identified using the sera of patients who had atopic dermatitis and a positive food challenge to peanut. The A r a h H allergen, having a molecular weight of 17 kD and a pI of 5.2, was isolated by anion exchange chromatography. Ara h H may be used to detect and quantify peanut allergens in foodstuffs.
5558984 A U T O M A T E D SYSTEM A N D PROCESS FOR HETEROTROPHIC GROWTH OF PLANT TISSUE Young Roy E; Hale S Andre Six Mile, SC, UNITED STATES Assigned to Clemson University A micropropagation system and process for promoting the growth of plant tissue in a sterile environment is provided. The system includes a bioreactor in which the explant tissue is contained and grown. A plurality of fuid reservoirs are connected to the bioreactor for supplying sugar, nutrients, hormones, and water to the plant material. A controller and an analyzer are also included for automating the system by controlling flow rates and by monitoring media concentrations and levels within the bioreactor. Specifically, the controller is capable of monitoring system conditions and making the desired corrections by receiving data from the chemical analyzer. In particular, the controller is
capable of calculatingand maintaining volume levels of fiquid growth media within the bioreactor chamber and maintainingthe proper ceocanwations and proportions of components in the growth media.
interference by the cellularcomponents of whole blood. The method includes contacting the whole blood with a test device including a filter pad comprising a suitable carrier matrix homogeneously incorporating therein a separating reagent composition comprising a) separating reagent, like an agglutinin, such as a blood type nonspecific lectin; a coagulant, such as a thrombin or a thrombin-like compound; or a mixture thereof, and b) a nonhamolyticsurfactant, like an ethoxylated or propoxylated nonionic or anionic surfactant, such that the cellular components of the whole blood are separated from the plasma or serum as the blood permeates through the filter pad, The essentially cell-free plasma or serum then saturates a test pad that is in contact with the ftlter pad. After the plasma or serum saturates the test pad, the test pad is examined for a qualitative or quantitative response to a predetermined soluble constituent of the whole blood.
5558865 HIV I M M U N O T H E R A P E U T I C S Ohno Tsuueya Boston, MA, UNH'ED STATES Assigned to Nissin Shokuhin Kabushiki Kaisha The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gpl20 protein or its precursor gpl60 protein comprising the amino acid sequence set out in SEQ ID NO: 1,G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-I strains MN and f I B as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC liB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV- 1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC FIB 10726 are specifically disclosed. Pharmaceutical compositions of the invention are projected to be useful in the passive iltllnuDiT~tion treatment of animals, especially humans, susceptible to or infected with HIV-I.
445
5558869 M A J O R PEANUT A L L E R G E N ARAHH Burks A Wesley; Helm Ricki M Little Rock, AR, UNITED STATES Assigned to University of Arkansas Peanut allergen Ara h H was identified using the sera of patients who had atopic dermatitis and a positive food challenge to peanut. The A r a h H allergen, having a molecular weight of 17 kD and a pI of 5.2, was isolated by anion exchange chromatography. Ara h H may be used to detect and quantify peanut allergens in foodstuffs.
5558984 A U T O M A T E D SYSTEM A N D PROCESS FOR HETEROTROPHIC GROWTH OF PLANT TISSUE Young Roy E; Hale S Andre Six Mile, SC, UNITED STATES Assigned to Clemson University A micropropagation system and process for promoting the growth of plant tissue in a sterile environment is provided. The system includes a bioreactor in which the explant tissue is contained and grown. A plurality of fuid reservoirs are connected to the bioreactor for supplying sugar, nutrients, hormones, and water to the plant material. A controller and an analyzer are also included for automating the system by controlling flow rates and by monitoring media concentrations and levels within the bioreactor. Specifically, the controller is capable of monitoring system conditions and making the desired corrections by receiving data from the chemical analyzer. In particular, the controller is
capable of calculatingand maintaining volume levels of fiquid growth media within the bioreactor chamber and maintainingthe proper ceocanwations and proportions of components in the growth media.